Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AMRI Acquires Pilot Plant Facilities in India | Contract Pharma

What are you searching for?

Sign in
Breaking News

AMRI Acquires Pilot Plant Facilities in India

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI has purchased FineKem Laboratories Pvt. Ltd., a manufacturing facility located in Aurangabad, India. This acquisition will add to the company’s ability to make custom pilot scale intermediates in India, which is expected to begin 2Q2008, and also adds another compound, ISMN (Isosorbide Mononitrate), to AMRI’s generics portfolio.
   
In the next few months, AMRI plans to upgrade the existing facilities to make them compliant with FDA regulations for manufacturing clinical trial materials and commercial drug substances.
   
FineKem’s managing director, Rakesh Doshi, will join AMRI India PVT Ltd. as executive director and chief operating officer reporting to Dr. Prasad Raje, managing director of AMRI’s current Aurangabad and Navi Mumbai facilities.
   
“We are pleased to announce the addition of this new product offering,” said AMRI chairman, president and chief executive officer, Thomas E. D’Ambra, Ph.D. “As we continue to explore and expand the ability of AMRI to provide value and flexibility around the globe, the purchase of this site increases the cost-competitive solutions available to our customers for their outsourcing needs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics